Core Thesis - Afya Limited is viewed as a compelling investment opportunity due to its strong market position in Brazil's medical education sector, despite recent volatility in its stock price [2][5] Company Overview - Afya Limited operates as a medical education group in Brazil, having evolved from a single family-run medical school in 1999 to a leading provider through acquisitions and organic growth [2][3] - The company went public on Nasdaq in 2019 and has since raised capital to support its expansion [2] Market Position - Afya is the leading medical education provider in Brazil, benefiting from a regulated seat-authorization system that protects incumbents from oversupply [3] - Major shareholders, including Bertelsmann, purchased shares at $26.90 in 2022 and are currently experiencing a value dislocation, indicating potential upside for new investors [3] Financial Performance - Revenue and profitability have increased significantly, supported by strong cash generation and modest leverage, despite challenges such as aggressive mergers and acquisitions and currency depreciation [4] - The company has maintained a stable share count while capitalizing on favorable long-term demand fundamentals, with Brazil expected to nearly double its physician base over the next decade [4] Management and Strategy - The management team, led by CEO Virgilio Gibbon since 2016, has shown consistent execution through the IPO process, acquisitions, and operational scaling [4] - Afya's operations are characterized by a mix of regulated scarcity and proven management, positioning it as an attractive candidate for further investment [5]